PetMed Express Announces Director Changes and Compensation Updates

Ticker: PETS · Form: 8-K · Filed: 2024-08-08T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

TL;DR

PetMed Express board shakeup and exec comp changes filed. New directors in.

AI Summary

On August 8, 2024, PetMed Express, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, including the appointment of a new Class II director, and changes to its executive compensation arrangements. Additionally, the filing covers the submission of matters to a vote of security holders and includes financial statements and exhibits.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Numbers

Key Players & Entities

FAQ

Who were the newly elected directors at PetMed Express?

The filing indicates the election of directors, including a new Class II director, but specific names are not detailed in the provided text.

What specific executive compensation arrangements were updated?

The filing mentions changes to compensatory arrangements of certain officers, but the specific details of these arrangements are not provided in this excerpt.

What matters were submitted to a vote of security holders?

The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not specified in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on August 8, 2024.

What is the principal executive office address for PetMed Express?

The principal executive offices are located at 420 South Congress Avenue, Delray Beach, Florida 33445.

From the Filing

0001040130-24-000081.txt : 20240808 0001040130-24-000081.hdr.sgml : 20240808 20240808171904 ACCESSION NUMBER: 0001040130-24-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PETMED EXPRESS INC CENTRAL INDEX KEY: 0001040130 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 650680967 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28827 FILM NUMBER: 241189677 BUSINESS ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 BUSINESS PHONE: (561) 426-4444 MAIL ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 8-K 1 pets-20240808.htm 8-K pets-20240808 0001040130 FALSE 0001040130 2024-08-08 2024-08-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  August 8, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 420 South Congress Avenue , Delray Beach , Florida 33445 (Address of principal executive offices) (Zip Code) ( 561 )  526-4444 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 per share PETS NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 8, 2024, the shareholders of PetMed Express, Inc. (the “Company”), upon recommendation of the Company’s Board of Directors (“Board”), approved the PetMed Express, Inc. 2024 Omnibus Incentive Plan (“2024 Plan”). The 2024 Plan is described in greater detail in proposal 3 in the Company’s Proxy Statement on Schedule 14A for the Company’s 2024 Annual Meeting of Shareholders (“Proxy Statement”). The Proxy Statement, which includes an a

View on Read The Filing